|
Real-world study to quantify the symptom and disease burden of central nervous system (CNS) metastases (mets) in non-small-cell-lung cancer (NSCLC). |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Research Funding - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Research Funding - Genentech |
|
|
Employment - Real World Economics and Consultancy |
Consulting or Advisory Role - Novartis |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
|
|
Consulting or Advisory Role - Idenix |
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche |